Home » Newsletters » BioWorld Science

BioWorld Science

June 5, 2007

View Archived Issues

New p38 MAPK inhibitors emerge from Ono R&D

Clinical trials of omalizumab therapy for asthma

Novel antiinfective agents disclosed in recent patent literature

Tanabe Seiyaku reviews domestic and overseas developments of past year

Desmoteplase fails to meet primary endpoint in acute ischemic stroke

Ecabet sodium demonstrates improvements in dry eye syndrome

Patent protection for administration of ChronVac-C by electroporation

Iroxanadine accelerates wound healing in diabetic animals

Positive preclinical findings reported for Scavidin

HalcyGen to develop antiinfectives licensed from Mayne Pharma

Medarex and Mitsubishi collaborate in autoimmune disease

New biomarkers point to Alzheimer's disease-linked inflammation in the brain

Peregrine enters development collaboration with Dios Therapeutics

Allos studies PDX and gemcitabine in NHL and Hodgkin's disease patients

Second approvable letter for Labopharm's once-daily tramadol

Phase III trial of Delcath System approved to expand into multiple sites

Neuro-Hitech obtains license to drug combinations for neuronal dysfunction

ThermoDox completes phase I study in nonresectable liver cancer

Transdermal low-dose contraceptive begins phase I pharmacokinetic program

Positive interim phase I findings for inhaled alpha-1 antitrypsin

Subcutaneous methylnaltrexone NDA accepted for review

Abbott seeks FDA approval of Xience V stent

Interim phase I results reported at ASCO for INNO-406, a dual Bcr-Abl/Lyn kinase inhibitor

Good safety demonstrated for a new antisense inhibitor of Akt-1

Investigators announce final results of phase II trial of anti-EpCAM antibody

Phase II dose and schedule of R-547 selected based on phase I data

AMG-655 shows good safety and evidence of activity in advanced cancer

Orally active PARP inhibitor proves safe and effective in ovarian cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...